Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark De Souza
AddedMar 31, 2024
UpdatedJun 28, 2026
Mark De Souza

Mark De Souza

Founder, Rnaderm Therapeutics

CrunchbaseLinkedIn

Mark De Souza's Career

Rnaderm Therapeutics
Rnaderm Therapeutics

Berkeley, CA, US

Founder
Willow Neuroscience
Willow Neuroscience

Emeryville, CA, US

Founder
Phoenicis
Phoenicis

Hingham, MA, US

Board Member· Board
FibRx Derm
FibRx Derm

Berkeley, CA, US

Co-Founder
Wings Therapeutics
Wings Therapeutics

Berkeley, CA, US

Founder
Myotherix
Myotherix

Union City, CA, US

Co-Founder
Flightpath Biosciences
Flightpath Biosciences

Berkeley, CA, US

Board Member· Board
Sonalasense
Sonalasense

Berkeley, CA, US

CEO· C-Suite · Management
Lotus Tissue Repair
Lotus Tissue Repair

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark De Souza's Career

Rnaderm Therapeutics
Rnaderm Therapeutics
Seed$750k52018Berkeley, CA, US
Founder
Willow Neuroscience
Willow Neuroscience
Seed$25.2k52016Emeryville, CA, US
Founder
Phoenicis
Phoenicis
Public$4.3M32020Hingham, MA, US
Board Member· Board

Leadership at Phoenicis

Deborah RamsdellDeborah RamsdellCo-Founder
FibRx Derm
FibRx Derm
Seed$1.8M62018Berkeley, CA, US
Co-Founder

Leadership at FibRx Derm

Erkki RuoslahtiErkki RuoslahtiCo-Founder
James FordyceJames FordyceCo-Founder

Similar to FibRx Derm

DermBiontDermBiontBoston, MA, USTherapeuticsest. 2017DermBiontBoston, MA, US · est. 2017

DermBiont: A leading precision dermatology firm, developing targeted therapeutics for skin health.

Series B · $108.5M47
Rnaderm TherapeuticsRnaderm TherapeuticsBerkeley, CA, USBiotechest. 2018Rnaderm TherapeuticsBerkeley, CA, US · est. 2018

Berkeley-based biotech company, RNADerm Therapeutics.

Seed · $750k5
ElucidermElucidermSan Diego, CA, USWound Healingest. 2018ElucidermSan Diego, CA, US · est. 2018

Eluciderm, a San Diego-based medical firm, innovates scarless wound healing products since 2018.

Seed · $2M5
SironRX TherapeuticsSironRX TherapeuticsCleveland, OH, USRegenerative Therapiesest. 2010SironRX TherapeuticsCleveland, OH, US · est. 2010

SironRX Therapeutics: Innovating regenerative therapies for wound repair and scar prevention in the US.

Series A · $3.9M6
Wings Therapeutics
Wings Therapeutics
Seed$1.5M52019Berkeley, CA, US
Founder
Myotherix
Myotherix
Pre-Seed$1M62013Union City, CA, US
Co-Founder

Leadership at Myotherix

John KincaidJohn KincaidCo-Founder
Michael G. KellyMichael G. KellyCo-Founder
Flightpath Biosciences
Flightpath Biosciences
Series A$1.1M82019Berkeley, CA, US
Board Member· Board

Leadership at Flightpath Biosciences

Curtis ScribnerCurtis ScribnerCo-Founder
Matthew TindallMatthew TindallCo-Founder

Similar to Flightpath Biosciences

X-Biotix TherapeuticsX-Biotix TherapeuticsWaltham, MA, USAntibioticsest. 2016X-Biotix TherapeuticsWaltham, MA, US · est. 2016

X-Biotix Therapeutics: A biotech firm innovating antibiotic solutions for multi-drug-resistant pathogens.

Series A · $7M9
ArrePathArrePathPrinceton, FL, USAnti-Infective Drugsest. 2022ArrePathPrinceton, FL, US · est. 2022

ArrePath: A biotech leader in discovering innovative anti-infective drugs using AI and imaging technologies.

Seed · $20M16
PhageProPhageProBoston, MA, USTherapeuticsest. 2016PhageProBoston, MA, US · est. 2016

PhagePro: Biotech firm developing bacteriophage-based therapeutics for vulnerable communities.

Seed · $3.1M5
Sonalasense
Sonalasense
Series B$21.1M142019Berkeley, CA, US
CEO· C-Suite · Management

Leadership at Sonalasense

Stuart MarcusStuart MarcusFounder
Lotus Tissue Repair
Lotus Tissue Repair
Series A$26M302010Cambridge, MA, US
Board Member· Board

Leadership at Lotus Tissue Repair

Mei-Ru ChenMei-Ru ChenCo-Founder
David WoodleyDavid WoodleyCo-Founder
James W Fordyce \"Jim\"James W Fordyce \"Jim\"Board Member

Similar to Lotus Tissue Repair

RenovoDermRenovoDermColumbus, OH, USWound Careest. 2016RenovoDermColumbus, OH, US · est. 2016

RenovoDerm: Ohio-based medical firm specializing in advanced wound care products since 2016.

Angel · $100k8
Biowound SolutionsBiowound SolutionsLas Vegas, NV, USWound Treatmentsest. 2023Biowound SolutionsLas Vegas, NV, US · est. 2023

Las Vegas-based Biowound Solutions develops and offers treatments for chronic wounds.

Seed · $3.6M50
BioTissueBioTissueMiami, FL, USTissue, Wound Healingest. 1997BioTissueMiami, FL, US · est. 1997

Biotissue Holdings Inc., a US-based company, specializes in regenerative wound healing using human birth tissues.

Public · $110M365

Mark De Souza's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Mark De Souza

Brad SmithBrad SmithCo-Founder & CEO · SonarAaron ZarragaAaron ZarragaCo-Founder · SenselRoss JasonRoss JasonCo-Founder · SonotizeMichael PhillipsMichael PhillipsBoard Member · EnglishCentralSascha HasanSascha HasanCo-Founder · BringhubFrank AdellFrank AdellCEO · Cognos Therapeutics